Our development programs represent the potential to improve the well-being of people whose lives are currently limited by rare disease.
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst’s core development programs include:
- BCX7353, an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE)
- BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases
- BCX9250, an oral ALK-2 inhibitor for treatment of Fibrodysplasia Ossificans Progressiva (FOP)
- BCX4430 (galidesivir), a broad-spectrum antiviral for hemorrhagic fevers
BioCryst’s discovery team is also designing drug candidates against additional undisclosed rare disease targets.
In December 2014, RAPIVAB® (peramivir injection) was approved by the FDA, the first FDA approval of a drug discovered by BioCryst.
For inquiries about licensing opportunities, please contact our business development group.
- Phase 1
- Phase 2
- Phase 3